Alyssa Skowronek
Family · Perryopolis, PANPI 1881314250
Payments from drug & device makers
Across 465 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$895
- AbbVie$781
- Novo Nordisk$781
- GSK$582
- Pfizer$560
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,008100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $1,078 |
| Lilly USA, LLC | 51 | $895 |
| AbbVie | 64 | $781 |
| Novo Nordisk | 57 | $781 |
| GSK | 39 | $582 |
| Pfizer | 37 | $560 |
| Amgen | 21 | $382 |
| Bayer | 22 | $330 |
| Boehringer Ingelheim | 16 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $286 |
| Exact Sciences | 14 | $274 |
| Boston Scientific | 2 | $216 |
| Merck | 8 | $153 |
| E.r. Squibb & Sons, L.L.C. | 8 | $152 |
| Astellas Pharma US Inc | 8 | $149 |
| Johnson & Johnson | 7 | $138 |
| Esperion Therapeutics, Inc. | 7 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $117 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| Phadia US Inc. | 4 | $78 |
| Seqirus USA Inc | 4 | $72 |
| Paratek Pharmaceuticals, Inc. | 3 | $51 |
| Dexcom, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $50 |
| Edwards Lifesciences | 2 | $45 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Cequr Corporation | 2 | $33 |
| Alkermes, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$302
- AIRSUPRA$302
- FARXIGA$302
- WATCHMAN FLX$216
How this compares
$8,008 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $91,206 |
| JardianceEmpagliflozin | 114 | $77,825 |
| OzempicSemaglutide | 59 | $71,741 |
| MounjaroTirzepatide | 60 | $62,233 |
| FarxigaDapagliflozin Propanediol | 75 | $56,964 |
| EliquisApixaban | 66 | $55,665 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $28,808 |
| BelbucaBuprenorphine Hcl | 25 | $21,434 |
| TrulicityDulaglutide | 12 | $20,779 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $19,214 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $14,017 |
| KerendiaFinerenone | 15 | $13,473 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $12,568 |
| XareltoRivaroxaban | 16 | $12,190 |
| RybelsusSemaglutide | 11 | $12,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $582 | $144,987273 claims |
| Novo NordiskOzempic, Rybelsus | $781 | $83,83170 claims |
| Lilly USA, LLCMounjaro, Trulicity | $895 | $83,01272 claims |
| Boehringer IngelheimJardiance | $296 | $77,825114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,078 | $69,53291 claims |
| PfizerEliquis, Paxlovid | $560 | $58,52484 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $41 | $21,43425 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $19 | $14,01715 claims |
| BayerKerendia | $330 | $13,47315 claims |
| Johnson & JohnsonXarelto | $138 | $12,19016 claims |
| AbbVieSynthroid | $781 | $1,55224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Perryopolis
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.